


**REMARKS**

By this Amendment, the Specification is amended, claims 1, 2 and 4-35 are canceled to place the application in better form for initial examination and allowance. Claim 3 is pending. Favorable examination on the merits is respectfully requested.

Should the Examiner believe that anything further is desirable in order to place the application in even better condition for allowance, the Examiner is invited to contact applicant's undersigned representative at the telephone number listed below.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be required by this paper or credit any overpayment to Account No. 18-1982.

Respectfully submitted,



Mark C. Nelligan, Reg. No. 36,389  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2388  
Telefax (908) 231-2626